-
52-week Open Label Safety-Tolerability Study
NCT07369154 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· New York: New York
-
A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
NCT07459647 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· New York: New York, Staten Island, The Bronx
-
A Mental Health Services Engagement Program for Racial and Ethnic Minority Young Adults
NCT06508450 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 34 Years ·
Sex: All (male and female)
· New York: The Bronx
-
A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia
NCT07423546 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 50 Years ·
Sex: All (male and female)
· New York: New York
-
A Study of Brenipatide in Adult Participants With Schizophrenia
NCT07410507 ·
Phase: Phase 2 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· New York: New York
-
A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
NCT07615426 ·
Phase: Phase 1 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· New York: Cedarhurst, Staten Island
-
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787 ·
Phase: Phase 3 ·
Ages: 55 Years to 90 Years ·
Sex: All (male and female)
· New York: New Windsor, Syracuse, Woodmere
-
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
NCT07288567 ·
Phase: Phase 3 ·
Ages: 13 Years to 17 Years ·
Sex: All (male and female)
· New York: Great Neck
-
A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively
NCT07424404 ·
Phase: Phase 3 ·
Ages: 5 Years to 17 Years ·
Sex: All (male and female)
· New York: Great Neck, Staten Island, The Bronx
-
A Virtual Reality Mindfulness Application for Aggression in Schizophrenia
NCT07434479 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 64 Years ·
Sex: All (male and female)
· New York: New York, White Plains
-
Biomarkers to Enhance Early Schizophrenia Treatment
NCT06969755 ·
Phase: Phase 4 ·
Ages: 18 Years to 35 Years ·
Sex: All (male and female)
· New York: Glen Oaks
-
Cerebellum-based Imaging Neural Markers for Antipsychotic Response
NCT07483294 ·
Phase: Phase 4 ·
Ages: 15 Years to 40 Years ·
Sex: All (male and female)
· New York: Glen Oaks
-
Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric Disorders
NCT05656469 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 16 Years to 70 Years ·
Sex: All (male and female)
· New York: Syracuse
-
Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
NCT05208190 ·
Phase: Phase 4 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· New York: New York
-
Digital Strategies to Advance Help-Seeking - Aim 3
NCT06774417 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 12 Years to 29 Years ·
Sex: All (male and female)
· New York: New York
-
Digital Strategies to Advance Help-Seeking Aim 1 and 2
NCT06774430 ·
Phase: Not specified ·
Ages: 12 Years to 29 Years ·
Sex: All (male and female)
· New York: New York
-
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
NCT07379827 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Buffalo, Monsey, Rochester, White Plains
-
Effectiveness of Motivation Skills Training (MST)
NCT05805397 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· New York: New York
-
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
NCT03817502 ·
Phase: Phase 3 ·
Ages: 13 Years to 17 Years ·
Sex: All (male and female)
· New York: Buffalo, New York
-
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
NCT07227818 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· New York: Cedarhurst, New York, The Bronx
-
Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
NCT07101094 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
NCT07184619 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
Exercise and Olanzapine-samidorphan
NCT06740890 ·
Phase: Phase 4 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· New York: New York
-
Impact of Cerebellar TMS on Brain and Cognitive Functions in Schizophrenia: a Pilot Study
NCT05389787 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female)
· New York: New York
-
MicroRNAs as Biomarkers in First Episode Schizophrenia
NCT07703670 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 15 Years to 40 Years ·
Sex: All (male and female)
· New York: Glen Oaks
-
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
NCT06963034 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· New York: Staten Island, The Bronx
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
NCT07114874 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· New York: Cedarhurst, New York, Staten Island, The Bronx
-
Neural Biomarkers of Electroconvulsive Therapy Response
NCT04763655 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· New York: Glen Oaks
-
Non-invasive Brain Stimulation Using Tdcs of the Third (of Many) Visual Pathways
NCT07469384 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· New York: Orangeburg
-
Randomized Withdrawal Study in Patients With Schizophrenia
NCT06961968 ·
Phase: Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· New York: Staten Island
-
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
NCT06229210 ·
Phase: Phase 3 ·
Ages: 5 Years to 17 Years ·
Sex: All (male and female)
· New York: New York, Staten Island
-
Study of ALTO-101 in Patients With Schizophrenia
NCT06502964 ·
Phase: Phase 2 ·
Ages: 21 Years to 55 Years ·
Sex: All (male and female)
· New York: New York, White Plains
-
Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
NCT07565428 ·
Phase: Phase 3 ·
Ages: 18 Years to 55 Years ·
Sex: All (male and female)
· New York: New York
-
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
NCT05303064 ·
Phase: Phase 3 ·
Ages: 10 Years to 17 Years ·
Sex: All (male and female)
· New York: New York
-
Targeting Processing Speed Deficits to Improve Social Functioning and Lower Psychosis Risk
NCT05131035 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 14 Years to 20 Years ·
Sex: All (male and female)
· New York: Glen Oaks
-
Tau Biomarkers in Late-onset Psychosis (LOP)
NCT06336382 ·
Phase: Not specified ·
Ages: 65 Years to 85 Years ·
Sex: All (male and female)
· New York: Manhasset
-
Vaping and Smoking Project in People With Schizophrenia
NCT06944847 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 21 Years to 50 Years ·
Sex: All (male and female)
· New York: Buffalo
-
Visual Perception in Schizophrenia
NCT06911931 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· New York: Rochester
-
iTBS to Enhance Social Cognition in People With Psychosis
NCT06118268 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 39 Years ·
Sex: All (male and female)
· New York: Glen Oaks